HIV Prevention Trials Network (HPTN); an international research consortium announced positive research findings which showed that an injectable HIV drug (Cabotegravir) was highly effective in preventing HIV for two months. The research trial; named HPTN 084 was done in seven African countries, including Uganda. Baylor-Uganda Centre of Excellence HIV clinic in Mulago was among the research sites where the study was carried out. These new results are an exciting addition to the HIV prevention methods already being used globally and there is hope that this will empower “at risk” populations to remain HIV negative.